A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer

M. J. Lind, S. Gomm, A. P. Simmonds, L. Ashcroft, A. Kamthan, H. Gurney, N. Thatcher

Research output: Contribution to journalArticleResearchpeer-review

Abstract

A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.

LanguageEnglish
Pages142-144
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume28
Issue number2
DOIs
Publication statusPublished - Mar 1991
Externally publishedYes

Fingerprint

interferon alfa-2b
Ifosfamide
Non-Small Cell Lung Carcinoma
Interferons
Toxicity
Cells
Therapeutics

Cite this

Lind, M. J. ; Gomm, S. ; Simmonds, A. P. ; Ashcroft, L. ; Kamthan, A. ; Gurney, H. ; Thatcher, N. / A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer. In: Cancer Chemotherapy and Pharmacology. 1991 ; Vol. 28, No. 2. pp. 142-144.
@article{a278562434da483f96d66587d17b60f5,
title = "A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer",
abstract = "A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.",
author = "Lind, {M. J.} and S. Gomm and Simmonds, {A. P.} and L. Ashcroft and A. Kamthan and H. Gurney and N. Thatcher",
year = "1991",
month = "3",
doi = "10.1007/BF00689705",
language = "English",
volume = "28",
pages = "142--144",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer, Springer Nature",
number = "2",

}

A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer. / Lind, M. J.; Gomm, S.; Simmonds, A. P.; Ashcroft, L.; Kamthan, A.; Gurney, H.; Thatcher, N.

In: Cancer Chemotherapy and Pharmacology, Vol. 28, No. 2, 03.1991, p. 142-144.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer

AU - Lind, M. J.

AU - Gomm, S.

AU - Simmonds, A. P.

AU - Ashcroft, L.

AU - Kamthan, A.

AU - Gurney, H.

AU - Thatcher, N.

PY - 1991/3

Y1 - 1991/3

N2 - A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.

AB - A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025890057&partnerID=8YFLogxK

U2 - 10.1007/BF00689705

DO - 10.1007/BF00689705

M3 - Article

VL - 28

SP - 142

EP - 144

JO - Cancer Chemotherapy and Pharmacology

T2 - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -